GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

Phase 3

Completed

Conditions: Haemophilus Influenzae Type b
Neisseria Meningitidis

Interventions: Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014
Biological: ActHIB
Biological: Pediarix/Infanrix Penta

First Posted Date: 2006-06-28

Last Posted Date: 2016-12-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 4432

Registration Number: NCT00345579

Locations: 🇲🇽
GSK Investigational Site, Mexico, D.F., Mexico

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

Phase 3

Completed

Conditions: Haemophilus Influenzae Type b
Neisseria Meningitidis

Interventions: Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)
Biological: PedvaxHIB
Biological: Prevnar
Biological: M-M-R II
Biological: Varivax

First Posted Date: 2006-06-28

Last Posted Date: 2016-11-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 4021

Registration Number: NCT00345683

Locations: 🇲🇽
GSK Investigational Site, Mexico, D.F., Mexico

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Phase 3

Completed

Conditions: Infections, Streptococcal

Interventions: Biological: Synflorix
Biological: Infanrix IPV/Hib

First Posted Date: 2006-06-28

Last Posted Date: 2019-01-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 600

Registration Number: NCT00345358

Locations: 🇫🇮
GSK Investigational Site, Vantaa, Finland

Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF)

Phase 4

Completed

Conditions: Heart Failure, Congestive

First Posted Date: 2006-06-26

Last Posted Date: 2020-11-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 50000

Registration Number: NCT00344513

Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria

Phase 3

Completed

Conditions: Malaria, Falciparum

Interventions: Drug: chlorproguanil-dapsone-artesunate
Drug: artemether-lumefantrine

First Posted Date: 2006-06-26

Last Posted Date: 2016-12-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1395

Registration Number: NCT00344006

Locations: 🇹🇿
GSK Investigational Site, Ifakara, Tanzania

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Phase 3

Completed

Conditions: Infections, Streptococcal

Interventions: Biological: Prevenar
Biological: Pneumococcal conjugate vaccine GSK1024850A
Biological: Tritanrix-HepB
Biological: Hiberix
Biological: Polio Sabin.
Biological: Poliorix.